Edition:
United States

People: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

117.95EUR
11:35am EDT
Change (% chg)

€-0.75 (-0.63%)
Prev Close
€118.70
Open
€119.15
Day's High
€119.55
Day's Low
€117.20
Volume
1,872,387
Avg. Vol
1,883,199
52-wk High
€123.90
52-wk Low
€86.03

Malik, Kemal 

Dr. Kemal Malik has been Member of the Management Board for Innovation and the Latin America Region at Bayer Aktiengesellschaft since February 1, 2014. He studied medicine at Charing Cross and Westminster Medical School (University of London), graduating as a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1987. He subsequently spent several years in clinical medicine at the Northwick Park Clinical Research Centre and at Hammersmith Hospital, London. He then held various positions of increasing responsibility in medical affairs and clinical development at Bristol-Myers Squibb in the United Kingdom. Malik joined Bayer in 1995 as Head of Metabolism and Oncology Europe in the then Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development. He was Member of the Executive Committee of Bayer HealthCare AG from July 1, 2007 until his appointment to the Board of Management of Bayer AG. He was also Head of Global Development and Chief Medical Officer in the Pharmaceuticals Division.

Basic Compensation

Total Annual Compensation, EUR 2,178,000
Restricted Stock Awards, EUR --
Long-Term Incentive Plans, EUR 1,573,000
All Other, EUR --
Fiscal Year Total, EUR 3,751,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Werner Wenning

369,000

Werner Baumann

6,408,000

Oliver Zuehlke

249,000

Johannes Dietsch

3,651,000

Hartmut Klusik

3,781,000

Liam Condon

3,904,000
As Of  30 Dec 2016